Free Trial
LON:SLN

Silence Therapeutics (SLN) Share Price, News & Analysis

Silence Therapeutics logo

About Silence Therapeutics Stock (LON:SLN)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLN Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Silence Therapeutics PLC Sponsored ADR
See More Headlines

SLN Stock Analysis - Frequently Asked Questions

Silence Therapeutics plc (LON:SLN) announced its quarterly earnings results on Monday, September, 14th. The company reported GBX (13.70) EPS for the quarter, beating the consensus estimate of GBX (21.70) by GBX 8.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include AB Dynamics (ABDP), Alfa Financial Software (ALFA), Asiamet Resources (ARS), Avast (AVST), AstraZeneca (AZN), Alkermes (ALKS) and Anchiano Therapeutics (ANCN).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
LON:SLN
CIK
N/A
Fax
N/A
Employees
100
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.80
Current Ratio
4.52
Quick Ratio
4.36

Sales & Book Value

Annual Sales
£11.35 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
6.34
Book Value
GBX 18.20 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
89,785,000
Free Float
N/A
Market Cap
£480.35 million
Optionable
Not Optionable
Beta
N/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (LON:SLN) was last updated on 11/29/2021 by MarketBeat.com Staff.
From Our Partners